2BBBullish & Bearish
Editas Medicine, Inc. (EDIT) trades on NASDAQ. It operates in the Health Care sector, Biotechnology industry. Its current 2BB score is 58 out of 100.
Editas Medicine, Inc., is a clinical-stage biotechnology company which is developing therapies for rare diseases based on CRISPR gene editing technology. Editas headquarters is located in Cambridge, Massachusetts and has facilities in Boulder, Colorado.
Editas Medicine, Inc.’s current 2BB score is 58 out of 100, built from the signal categories below.
| Signal | Score | Reading |
|---|---|---|
| Activity | 67 | High |
| Momentum | 75 | Improving |
| Financial strength | 14 | Very Weak |
| Quality | 80 | Very Strong |
| Risk | 52 | Moderate |
| Founded | Nov 2013 |
| Employees | 87 |
| 52-week range | $1.66 – $4.54 |
| Report date | EPS actual | EPS estimate | Revenue actual | Revenue estimate |
|---|---|---|---|---|
| 2026-11-09 | — | -0.1941 | — | $3.82M |
| 2026-08-05 | — | -0.2735 | — | $2.86M |
| 2026-05-05 | -0.26 | -0.269 | $2.83M | $4.49M |
| 2026-03-09 | -0.06 | -0.2633 | $24.74M | $5.71M |